Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) as Milestone Drives 1Q Beat
May 10, 2016 6:43 AM EDTMizuho Securities reiterated a Buy rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $16.00 (from $15.00), following the company's 1Q earnings report. IRWD reported $66M in revenues and loss of ($0.08) per share, both ahead of consensus estimates of $53.6M and ($0.14). The beat can be... More
Ironwood Pharma (IRWD) Tops Q1 EPS by 6c
May 9, 2016 4:17 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.08), $0.06 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $66 million versus the consensus estimate of $53.58 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More